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ABSTRACT 
 
Background: Generic medicines have the same efficacy and safety as originators at lower prices. 
However, there are concerns with their utilization in Nigeria. Objectives: EYDOXDWHSK\VLFLDQV¶
understanding and perception of generics. Methods: Questionnaire among physicians working in 
tertiary healthcare facilities in four geo-political regions of Nigeria. Results: Response was 74.3% 
(191/257) among mainly males (85.9%). The mean knowledge score regarding generics was 5.3 
(maximum of 9) with 36.6%, 36.1% and 27.2% having poor, average and good knowledge 
respectively. Cross-tabulation showed statistical significance (P = 0.047) with the duration of practice 
but not with position, subspecialty or sex. The majority did not agree that generic medicines are of 
lower quality than branded medicines. Therapeutic failure was a major concern in 82.7%, potentially 
discouraging prescribing of generics. Majority (63.9%) did not support generic substitution by 
pharmacists. Conclusion: Knowledge gaps were identified especially with the perception of generics. 
These need to be addressed.   
 
INTRODUCTION 
 
Generic medicines have the same quality, efficacy and safety properties as originator (branded) 
medicines while being available at more affordable prices (1-5). According to the United States Food 
and Drug Administration (FDA), a generic drug product is one that is comparable to an innovator drug 
product in dosage form, strength, route of administration, quality, performance characteristics and 
intended use. These are similar definitions in Europe (2, 6). As a result, published studies from these 
countries have shown similar effectiveness rates between generics and originators (brand name 
medicines) across a range of classes. These include medicines for infectious and cardiovascular 
diseases as well as mental health (7-13). 
 
The increasing need for good quality low costs generic medicines has arisen with pharmaceutical 
expenditure growing by more than 50% in real terms among OECD (Organisation for Economic Co-
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operation and Development) countries during the past decade (14), with expenditure on medicines 
accounting for up to 60% of total healthcare expenditure in some countries (15). This growth in 
pharmaceutical expenditure has been driven by well know factors. These include the increasing 
prevalence of non-communicable diseases, enhanced by growing elderly populations in a number of 
continents including Europe, and the continued launch of new higher priced medicines (16, 17).  This 
has resulted in health authorities introducing measures to moderate pharmaceutical expenditure 
without compromising care (18, 19).This includes initiatives to increase the prescribing and 
dispensing of low cost generics versus originators (brand named medicines). Measures and initiatives 
include educational activities among physicians and patients, reference pricing in a class with patients 
covering the additional costs themselves for a more expensive molecule, financial incentives for 
physicians, compulsory generic substitution in pharmacies, substitution targets in pharmacies as well 
as compulsory International Nonproprietary name (INN) prescribing; alternatively education and other 
measures to ensure high voluntary INN prescribing (4, 18, 20-29). In their study, Cameron and 
colleagues believed up to 89% of the cost of medicines could be saved among developing countries 
from switching patients from originator brands to the lowest priced generics (5). Policies to enhance 
the prescribing and dispensing of generics in France OHGWRDQQXDOVDYLQJVHVWLPDWHGDW¼EQLQ
¼EQLQDQG¼EQLQ(19). The use of generic medicines versus more expensive 
branded (originator) medicines has also been shown to positively impact on medication adherence, 
appreciably impacting on disease progression and the overall health of the population (30, 31). 
 
There have also been initiatives across countries to increase the prescribing of low cost generics 
versus patented products in a class where all products in the class are seen as essentially similar at 
therapeutic doses. These classes include the proton pump inhibitors (PPIs), renin-angiotensin 
inhibitors and statins (17, 25, 32-36). Published studies have again shown that patient care is not 
compromised (32, 36-39), whilst moderating or even reducing pharmaceutical expenditure despite 
increasing utilisation (17, 25, 36, 40-42).  
 
However, there are countries where the prescribing and dispensing of generics versus originators is 
suboptimal. The reasons for this include physicianV¶ concerns with the safety, efficacy, and 
bioequivalence of generics versus originators, ease of remembering brand names as well as 
pharmaceutical company activities promoting concerns with generics (43-50). These differences in 
perceptions regarding generics have resulted in very different utilization rates for generics across 
countries. For instance, there is high acceptance of generics among physicians in the UK translating 
into very high voluntary INN prescribing rates apart from a limited number of situations including 
certain combination products, lithium, theophyllines and certain medicines to treat epilepsy (24, 25, 
51-53).. A variety of educational and other initiatives in the UK have resulted in INN prescribing at 
98% to 99% of medicines once they are available as generics across a range of classes where there 
are no issues with substitution (25). In Malaysia, 85.1% of physicians routinely prescribed generic 
drugs, although this figure was lower among physicians in private medical centers (43, 50). This 
contrasts with Italy where a survey conducted between January and March 2011 ascertained that 
87% of pediatricians do not prescribe generics due to concerns (54).  
 
Results from several studies in Nigeria have shown that only 42% to 50% of all medications were 
prescribed by their generic name (55-57).  This low rate of generic medicine prescribing contradicts 
the National Standard Treatment Guidelines, which stipulates that medicines should be prescribed in 
their generic form, i.e. INN prescribing (58). In Nigeria, the National Agency for Food and Drug 
Administration  (NAFDAC) is the main regulatory body for medicines including biologicals, responsible 
for marketing authorization of all medications ± generics and branded medicines - in the country (59).  
At the same time, the healthcare sector in Nigeria is under-funded, accounting for less than 6% of the 
FRXQWU\¶s  GDP between 2010 and 2012, while the proportion of federal government revenue 
expended on healthcare was 3.5% in 2010 (60, 61). Several studies have shown that out of pocket 
spending (OOP) in Nigeria constitutes the major form of healthcare expenditure among the 
population, which can be as high as 62% of total healthcare expenditure (61-64). This will impact on 
available choices of medicines to treat diseases as well as potential compliance, especially in patients 
with chronic diseases (65-67). The National Health Insurance Scheme (NHIS), which commenced 
operations in 2005, was introduced to address some of these issues and concerns; however, LW¶V
coverage has remained below 5% of the total population (68).   
   
3 
 
Increased prescribing of lower cost generic medicines could lead to a reduction in healthcare costs as 
well as OOP for patients. In addition, offering dispensers the freedom to choose from a wide variety of 
available generic medicines. However, there are barriers to address including concerns with their 
efficacy and safety.  
. 
However, information regarding the knowledge, perception and attitude of Nigerian physicians 
towards generic medicines is lacking. This needs to be addressed in order to develop robust policies 
to overcome potential misinformation and misconceptions concerning generic medicines. 
Consequently, the primary objective of this study is tRHYDOXDWHSK\VLFLDQV¶XQGHUVWDQGLQJRIWKH
FRQFHSWRI³JHQHULFPHGLFLQHV´. Additional objectives include evaluating physicians¶SHUFHSWLRQRI
generic medicines including their safety, efficacy and bioequivalence versus brand name (originator) 
medicines as well as DVVHVVSK\VLFLDQV¶Srescribing of generic medicines. Subsequently, use the 
findings to suggest future activities in Nigeria to enhance the prescribing of generics. 
  
METHODS 
 
x Study design 
 
This was a cross-sectional and questionnaire-based study conducted during the months of June to 
December, 2014. 
 
x Study Sites 
 
The study was conducted among medical doctors working in tertiary healthcare facilities located in 
four geo-political regions of Nigeria: south-west, south-east, north-central and north-west Nigeria.   
 
x Study Instrument 
 
The questionnaire, comprising  four sections, was adapted from  a previous study (69). It comprised 
sections on the general characteristics of the participants, assessment of SK\VLFLDQV¶XQGHUVWDQGLQJRI
the concept of generic medicines, their perception of their safety and efficacy as well as attitudes 
towards their prescribing.  
 
7KHVHFWLRQRQSK\VLFLDQV¶NQRZOHGJHFRQVLVWHGRIVWDWHPHQWVUHJDUGLQJWKHFRQFHSWRIJHQHUic 
medicines to which three questions had three options - <HV1RDQG'RQ¶W.QRZ. Each correct (Yes) 
response was scored 1 whilst ³1R´DQG³'RQ¶WNQRZ´ZHUHVFRUHG, making the total available score 
of 9.  Physicians¶NQRZOHGJH (knowledge level) was subsequently classified into poor (score <5), 
average (score 5-6) and good (score 7-9). The questionnaire was pilot- tested among ten medical 
doctors from a secondary level healthcare facility and necessary adjustments made to achieve the 
objectives before it being administered to the study participants. The internal consistency of the three 
SDUWVRIWKHTXHVWLRQQDLUHZDVFDOFXODWHG&URQEDFK¶VDOSKDZLWKWKHNQRZOHGJHSHUFHSWLRQDWWLWXGH
and practice aspects scoring 0.70, 0.62 and 0.76 respectively. 
 
We have divided medicines into brand name (originator) medicines and generics. We accept that 
branded generics are common in a number of countries. However, we wanted to avoid any confusion. 
We have made this distinction in a number of previous studies involving some of the co-authors when 
researching the utilization of generics, originators and patented products in a class (34, 42, 70-72). In 
addition, this was the definition of Cameron and colleagues from the WHO in their recent paper (5). 
 
x Sample size calculation 
 
The estimated sample size was 233 from a population of 1200 physicians from the four geo-political 
regions. Ten percent of the calculated sample size was added to cater for possible non ± responders 
and poorly completed questionnaires, making a total of 257. The sample size was calculated using 
the online statistical software from Raosoft Incorporated (73) . 
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x Sample Population/Selection 
 
Random sampling was used to select respondents among medical doctors working in tertiary 
healthcare facilities in the selected geo-political regions of Nigeria.  The names of all doctors 
(excluding medical interns) working in the hospitals were compiled from departmental duty rosters 
and participants were selected using a random technique ± dice rolling. Medical interns were 
excluded because of their lack of experience with prescribing. The selected medical doctors were 
approached during a departmental seminar in their different units and invited to participate in the 
study. Written informed consent was then obtained from those who agreed to participate in the study. 
The questionnaire was subsequently administered to those who agreed to take part and they were 
given approximately 30 minutes to complete it. The distribution and collection of the questionnaires 
was coordinated by a co-investigator and one research assistant in each of the participating centers. 
 
x Ethical consideration 
 
Ethical approval was obtained from relevant hospital authorities before commencement of the study. 
Confidentiality was maintained as respondents were advised not to disclose their identities in their 
completed questionnaires. 
 
The study was funded through contributions from all co-investigators 
 
x Statistical Analysis 
 
The information obtained from the questionnaire was coded, entered and analyzed using IBM 
compatible SPSS version 19. Analysis was undertaken using descriptive statistics to obtain the 
general characteristics of the study participants. Chi square was used to determine the level of 
significance of the groups of categorical variables. P values <0.05 were considered significant. 
 
RESULTS 
 
x General characteristics of respondents 
 
The response rate was 74.3% (191/257) with a preponderance of males (164/85.9%). Respondents 
comprised medical registrars (98/51.5%), medical officers (53/27.7%), senior registrars (27/14.1%) 
and consultants (13/6.7%). Most respondents worked in Internal medicine, followed by Surgery and 
Family Medicine (Figure 1). 
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Figure 1:  Frequency distribution of respondents (actual numbers) according to  their medical 
specialty  
 
 
The median duration of work experience (time since obtaining their medical degree) was 4 years with 
119 (62.3%), 50 (26.2%) and 22 (11.5%) having 1 to 5yrs, 6 to 10yrs and >10yrs work experience 
respectively. 
 
x Knowledge about generic medicines 
 
Generic medicines were recognized as copies of brand name (originator) medicines by only 44% of 
the respondents, whilst 47.1% were aware that generic medicines are interchangeable with brand 
name medicines (Table 1). The fact that generic medicines are therapeutically equivalent to brand 
name medicines was known by 97 (50.8%) of respondents.  Sixty-seven respondents (35.1%) did not 
NQRZWKDWJHQHULFPHGLFLQHVPXVWEHLQWKHVDPHGRVDJHIRUPDVLWV¶FRUUHVSRQGLQJEUDQGQDPH
medicines, with only 74 (38.7%) respondents aware of the time frame for licensing of  generic 
medicines (Table 1). 
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Table 1: The association of SK\VLFLDQV¶NQRZOHGJHDERXWJHQHULFPHGLFLQHVDQGVRPHFDWHJRULFDO
variables  
 
Statements Yes (%) No (%) 'RQ¶W
know 
(%) 
Position   
X2 (P-
value) 
Sex  
X2 (P-
value 
 
Duration 
X2 (P-
value 
Generic medicines are copy of 
brand name (originator) 
medicines 
84(44) 88(46.1) 19(9.9) 0.29 0.17 0.18 
Generic medicines are 
interchangeable with brand 
name (originator) medicines 
90(47.1) 86(45.0) 15(7.9) 0.001* 0.94 0.02* 
Generic medicines are 
therapeutically equivalent to 
brand name medicines  
97(50.8) 76(39.8) 18(9.4) 0.008* 0.92 0.40 
Generic medicines must be in 
the same dosage form (such as 
tablet, capsule) as brand name 
(originator) medicines 
124(64.9) 49(25.7) 18(9.4) 0.72 0.15 0.63 
Generic medicines are less safe 
than brand name (originator) 
medicines 
29(15.2) 139(72.8) 23(12.0) 0.05* 0.18 0.28 
Generic medicines are available 
in the market of Nigeria 
147(77.0) 27(14.1) 17(8.9) 0.56 0.35 0.22 
Generic medicines are 
manufactured after the 
expiration of the patent of the 
originator/innovator 
74(38.7) 67(35.1) 50(26.2) 0.02* 0.17 0.01* 
Brand name medicines are of 
better quality compared with 
generic medicines 
68(35.6) 109(57.1) 14(7.3) 0.045* 0.22 0.17 
Brand name (originator) 
medicines produce lesser side 
effects than generic medicines 
33(17.3) 132(69.1) 26(13.6) 0.83 0.01* 0.31 
NB: * denotes P value less than 0.05 (Statistical significance) 
 
The mean knowledge score recorded was 5.3 (SD 1.8) out of the total obtainable score of 9, with 70 
(36.6%), 69 (36.1%) and 52 (27.2%) of respondents having poor, average and good knowledge 
respectively. A comparison of the mean knowledge score among various categories (current position 
and duration of practice) showed significant statistical significance (P value of 0.02 and 0.01 
respectively). A box plot comparing the means of various cadres of respondents is shown in Figure 2.  
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Figure 2: Comparison of the mean knowledge score of various cadre of physicians  
 
 
 
7KHDVVRFLDWLRQRIUHVSRQGHQWV¶NQRZOHGJHSHUFHSWLRQDQGSUDFWLFHZLWKtheir positions, duration of 
practice and sex is shown in Tables 1 to 3.  
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7DEOH7KHSK\VLFLDQV¶SHUFHSWLRQof generic medicines with respect to categorical variables 
 
Statement Agree 
(%) 
'RQ¶W
Agree 
(%) 
No 
opinion 
(%) 
Position 
X2 (P 
value) 
Sex 
X2 (P 
value) 
Duration 
X2 (P 
value) 
Generic medicines are of low 
quality compared with brand 
name (originator) medicines 
41(21.5) 137(71.7) 13(6.8) 0.02* 0.51 0.67 
Generic medicines produce 
more adverse effects than 
brand name (originator) 
medicines 
29(15.2) 142(74.3) 20(10.5) 0.03* 0.14 0.28 
Low-priced medicines are as 
safe as high-priced medicines 
90(47.1) 72(37.7) 28(18.4) 0.99 0.08 0.84 
Drugs from multinational 
companies are of better  quality 
than medicines   produced by 
local companies 
90(47.1) 82(42.9) 19(9.9) 0.001* 0.31 0.09 
I believe that not all the local 
companies in Nigeria are 
following Good Manufacturing 
Practices (GMP) guidelines as 
multinationals 
139(72.8) 31(16.2) 21(11.0) 0.83 0.65 0.83 
Few local companies are 
reputable generic medicine 
manufacturers 
134(70.2) 30(15.7) 27(14.1) 0.09 0.28 0.24 
My prescribing decision is 
influenced by medical 
representatives 
39(20.4) 137(71.7) 15(7.9) 0.02* 0.31 0.19 
Doctors should be educated 
more about prices of medicines 
169(88.5) 11(5.8) 11(5.8) 0.23 0.09 0.87 
Doctors should be given 
incentives to write generic 
names 
34(17.8) 137(71.7) 20(10.5) 0.31 0.02* 0.95 
I think that confidence should be 
conveyed to the patient about 
the low-cost medicines 
136(71.2) 27(14.1) 28(14.7) 0.81 0.15 0.85 
I believe that it is easier to 
remember a brand name 
(originator) medicine than a 
generic 
94(49.2) 85(44.5) 12(6.3) 0.78 0.53 0.93 
NB: * denotes P value less than 0.05 (Statistical significance) 
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7DEOH7KHSK\VLFLDQV¶DWWLWXGHSUDFWLFHRIJHQHULFPHGLFLQHSUHVFULELQJwith respect to categorical 
variables (continued) 
 
Statement Agree 
(%) 
Disagree 
(%) 
Neutral 
(%) 
Position 
X2 (P 
value) 
Sex 
X2 (P 
value) 
Duration 
X2 (P 
value) 
I am concerned  about the 
therapeutic failures that are 
associated with some locally 
manufactured medicines 
158(82.7) 13(6.8) 20(10.5) 0.22 0.62 0.98 
I am hesitant to prescribe low-
priced medicines in some specific 
therapeutic classes in my practice 
143(74.9) 29(15.2) 19(9.9) 0.41 0.01* 0.96 
The socioeconomic condition of 
my patient sometimes influence 
the prescription given 
170(89) 13(6.8) 8(4.2) 0.76 0.08 0.56 
I am comfortable prescribing  
products from  local manufacturers 
79(41.4) 51(26.7) 61(31.9) 0.96 0.09 0.09 
My personal experience with 
medicines influence my prescribing 
decisions 
165(86.4) 12(6.3) 14(7.3) 0.91 0.09 0.77 
,IHHOWKDWSDWLHQW¶VGHPDQGRI
certain medicines influence my 
prescription 
43(22.5) 129(67.5) 19(9.9) 0.22 0.12 0.78 
Medical representatives are good 
sources of information for me 
85(44.5) 62(32.5) 44(23) 0.13 0.008* 0.86 
3KDUPDFHXWLFDOFRPSDQLHV¶
premium offers (gifts) influence my 
prescribing behaviour 
23(12.0) 135(70.7) 33(17.3) 0.54 0.01* 0.64 
I am comfortable if the brand name 
(originator) medicine in 
prescription is substituted by the 
pharmacist 
34(17.8) 122(63.9) 35(18.3) 0.03* 0.51 0.52 
I  usually prescribe generic 
medicines for my patients 
117(61.3) 37(19.4) 37(19.4) 0.55 0.008* 0.32 
NB: * denotes P value less than 0.05 (Statistical significance) 
 
Cross-tabulation of the knowledge level of respondents showed significant statistical significance (P = 
0.047) with duration of practice but not with position, subspecialty and sex (Table 4). 
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Table 4:   knowledge level of respondents according to some categorical variables 
 
Categorical variable Poor 
knowledge 
Average 
knowledge 
Good 
knowledge 
X2 (P value) 
Position     
Medical Officer 20 (37.7) 19 (35.9) 14 (26.4)  
Registrar 38 (38.8) 34 (34.7) 26 (26.5)  
Senior Registrar 10 (37.1) 12 (44.4) 5 (18.5)  
Consultants 2 (15.4) 4 (30.8) 7 (53.8) 0.361 
Duration (post qualification)     
1-5 years 45 (37.8) 46 (38.7) 28 (23.5)  
6 ± 10 years 19 (38.0) 19 (38.0) 12 (24.0)  
>10 years 6 (27.3) 4 (18.2) 12 (54.5) 0.047* 
Sex     
Male 58 (35.4) 60 (36.6) 46 (28.1)  
Female 12(44.5) 9 (33.3) 6 (22.2) 0.65 
NB: *Indicates P value less than 0.05 (Statistical significance) 
 
x Perception of doctors towards generic medicines 
 
The majority (71.7%) of respondents did not agree that generic medicines are of lower quality than 
branded medicines (Table 2). Only 29 (15.2%) respondents agreed that generic medicines produced 
more side-effects than brand name medicines while 90 (47.1%) felt that low-priced generic medicines 
are as safe as the expensive branded ones (Table 2).  
 
Regarding the quality of generic medicines produced by local drug manufacturers, 90 (47.1%) of 
respondents were of the opinion that they were of lower quality than those produced by multi-national 
pharmaceutical companies (Table 2). On the issue of Good Manufacturing Practice (GMP), 139 
(72.8%) respondents believe that few local companies observe GMP, hence only 30 (15.7%) view 
local manufacturers as reputable producers of generic drugs. On whether doctors should be given 
incentives to prescribe generic medicines, the majority (71.7%)  disagreed with this suggestion; 
whilst71.2% felt that patients should be educated about generic medicines to boost their confidence 
(Table 2). 
 
x Attitude/Practice of doctors towards prescribing generic medicines 
 
On the issue of therapeutic failures occurring with generic medicines, 158 (82.7%) respondents were 
seriously concerned discouraging them from prescribing low-priced generic medicines (Table 3). In 
fact, 74.9% stated their reluctance to prescribe generic medicines from some specific therapeutic 
classes based on these concerns (Table 3). Many (89%) of the respondents were also influenced by 
the socio-economic class of the patients and personal experience with the medicines (86.4%) when 
prescribing (Table 3).  
 
Eighty-five respondents (44.5%) believed that medical representatives are good sources of 
information regarding medicines whilst only 23 (12%) believed they are influenced by gifts from 
pharmaceutical companies (Table 3).  
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Finally, most of the physicians (63.9%) would not be comfortable if there was generic substitution of 
brand name (originator) medicines by pharmacists (Table 3). 
 
DISCUSSION 
 
This cross-national study is one of the few studies to date in Nigeria evaluating the knowledge, 
perception and attitude of medical doctors towards generic medicines. It has identified significant 
gaps in the knowledge and perception among physicians in Nigeria that may hamper the prescribing 
of generic medicines. 
 
Overall, we had a response rate to the questionnaire at close to 75%. This is close to 80% obtained in 
a similar study among Greek physicians (74). However, appreciably higher than a 36% response rate 
obtained in a questionnaire study to ascertain private physicians¶SHUFHSWLRQRIJHQHULFPHGLFLQHVLQ
Malaysia (50). It was also noticed that more junior medical doctors participated in our study. This 
though reflects the current distribution of medical doctors in many tertiary healthcare facilities in 
Nigeria. Results from surveys conducted among physicians have identified lack of time as the main 
reason for non-response (75, 76).  
 
We will first comment on the findings before suggesting potential ways forward in Nigeria to enhance 
the prescribing of generics.  
 
x Knowledge about generic medicines 
 
In this study, less than half of the respondents were aware of the definition of generic medicines as 
copy of the original brand and being interchangeable with it (Table 1). This was higher than some 
published studies but lower than others. Jamshed et al in their study among general practitioners in 
Pakistan found that 71.8% of respondents had the correct definition (69). However, Fabianio et al in 
their study found only 32.6% and 37.2% of Italian pediatricians were seen to have sufficient and good 
knowledge of generic medicines respectively (54).  In addition, only 2.3% to 4.6% of physicians in 
Malaysia correctly identified bioequivalence standards for generic medicines in recent studies (43, 
50).  
 
In this study, 63.7% of respondents had at least average knowledge about the concept of generic 
medicine, with those with more than 10 years post-graduation experience having a higher mean 
score. This finding is suggestive of a positive influence of post-graduate education and experience on 
SK\VLFLDQV¶NQRZOHGJHDERXWWKHFRQFHSWRIJHQHULFPHGLFLQHVThis was in contrast to the study by 
Awaisu et al among community pharmacists in Qatar, who found that work experience did not 
positively influence the knowledge of their respondents about generic medicines (77). The different 
findings may not be surprising as our study was conducted in tertiary healthcare facilities where the 
majority of respondents were involved with post-graduate medical education. The pharmacist studied 
by Awaisu et al might not be undergoing similar continual education. 
 
x Perception of doctors towards generic medicines 
 
As mentioned, most of the concerns regarding generic medicines revolve around their safety and 
efficacy versus originators (brand name medicines). This was a common finding in a recent 
systematic review regarding attitudes towards generics among physicians from low and middle 
income countries (78).  
 
In this study, 39.8% of respondents believed generic medicines were not therapeutically equivalent to 
brand named medicines and 35.6% believed brand named medicines were of better quality (Table 1). 
However, 69.1% did not believe brand named (originator) medicines produce less side-effects and 
only 15.2% of respondents believed generic medicines are less safe (Tables 1 and 2). This was lower 
than 41.3% of respondents in the study by Jamshed (69) and 42.2% of private physicians in Malaysia, 
who believed generic medicines produce more side-effects than brand named medicines (50). In 
addition,  lower than Zaoui et al in their study conducted in Morocco found that 68% of respondents 
believed generic drugs were not always effective (79).  
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The possibility of therapeutic failure is a major concern among physicians when prescribing generic 
medicines. In this study, 82.7% of respondents were worried about the possibility of treatment failure 
and 74.9% would hesitate to prescribe generics from certain therapeutic classes (Table 3). The issue 
of therapeutic failure is directly related to that of bioequivalence (80, 81). In the study by Zaoui in 
Morocco, 70% of respondents would prescribe generic drugs if bioequivalence to branded medicines 
is ascertained (79). In the study among community pharmacists in Qatar, the lack of proven 
bioequivalence to branded medicines is a major hindrance to the prescribing of generic medicines 
(77).  
 
The view of majority of respondents in this study (70.2% - Table 2) that only a few local companies 
are reputable manufacturers of generic drugs is a cause for concern. Building trust and capacity in the 
local manufacture of generics will help to lower costs and enable the manufacturers in Nigeria to 
compete globally.  
 
x Attitude/Practice of doctors towards prescribing generic medicines 
 
The relationship between the pharmaceutical industry and medical practitioners has attracted 
considerable debate globally (82-88).  
 
In our study, 12.0% of respondents admitted their prescribing practices are influenced by gifts from 
pharmaceutical companies and 44.5% believed medical representatives were a good source of 
information regarding medicines (Table 3). This is similar to the study by Kersnik et al among 
pharmacists and prescribers in Slovenia, who found only 15.5% of prescribers considered their 
prescribing was influenced by pharmaceutical representatives (89).  However, lower than  the study 
by Riaz et al in Pakistan who found that 68% to 86% of the physicians surveyed obtained their 
knowledge of medicines from medical representatives (90). 
 
The importance of knowing the costs of medications being prescribed cannot be over-emphasized as 
it contributes to rational use of medications. In this study, 88.5% of respondents agreed that medical 
doctors should be educated about the costs of medicine (Table 2). Toklu et al in their study conducted 
in Turkey also reported that 92% of prescribers took cost of medicines into consideration when 
prescribing (91).  
 
x Future suggestions and initiatives 
 
This study identified a number of gaps especially in the areas of perception and practice of generic 
medicines and their prescribing by physicians in Nigeria.  
 
The perception of poor quality of generic medicines by respondents in this study resonates with the 
widespread problems of sub-standard medication that has attracted a lot of attention in recent times 
(92, 93). The role of the World Health Organization (WHO) and other international donor agencies in 
ensuring the provision of quality generic medicines for diseases such as malaria, TB and HIV has 
SRVLWLYHO\LPSDFWHGSDWLHQWV¶RXWFRPHV(94). Expanding this pre-qualification process to other 
essential medicines, especially for non-communicable diseases like hypertension and diabetes 
mellitus, would most likely have a similar effect.  Also, strict regulations including proven 
bioequivalence of PHGLFLQHVZRXOGSURPRWHSK\VLFLDQV¶FRQILGHQFHLQSUHVFULELQJJHQHULFV(95). 
 
The findings suggest there is an urgent need in Nigeria to build up the trust of prescribers in generic 
medicines to save costs for patients and the health service. This can be achieved through instigating 
mandatory quality assurance programmes among local generic manufacturers, as well as the 
statutory provision of the bioequivalence data and standards, given that 72.8% had concerns with 
local manufacturers (Table 2). This mirrors practices in the US and Europe (2). Such measures 
should enhance physician trust regarding local generic manufacturers, and enhance their potential for 
export across Africa and more widely.  
 
The findings also suggest there is a need to instigate measures to enhance the prescribing of 
generics versus brand named (originator) medicines in line with the National Standard Treatment 
Guidelines in Nigeria (58). Measures could include routine encouragement of INN prescribing apart 
from a limited number of situations, starting with training in medical school similar to the UK (25). This 
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includes educating physicians on issues such as bioequivalence for generics  to address 
misconceptions (2). In addition, emphasizing that the prescribing of good quality generics should not 
compromise care as seen by published studies across a range of disease areas (7-13).  
 
Generic substitution has also been one of the measures adopted by many countries to enhance the 
use of generic medicines (1). However, the majority (63.9%) of respondents in this study did not 
support generic substitution by the pharmacists (Table 3). This is similar to other findings depending 
on the faith physicians have in their regulatory system as well as other factors. 68% of prescribers in a 
study conducted in Morocco rejected generic substitution because it infringed on their prescribing 
freedom whilst 35.6% of patients in a Nigerian study rejected generic substitution at some time (79, 
96). In a study conducted among drug retailers and community pharmacists in India, 80% of 
respondents rejected generic substitution(97). However, Awaisu et al found that 72% of community 
pharmacists supported generic substitution (77). Generic substitution is also generally supported by 
key stakeholder groups in Sweden to help conserve costs (26, 98, 99). These differences in opinion 
may be due to inter-professional conflicts between physicians and pharmacists, the practice 
environment (country), perceived differences between generic products and brand named products as 
well as personal experience with generic and brand named (originator) products.  
 
There also needs to be an increase in continual professional development activities among physicians 
in Nigeria, including education from Drugs and Therapeutics Committees, to reduce the reliance on 
the pharmaceutical industry for education about medicines (Table 3). 
 
We are aware that there are limitations with this study.  We acknowledge that this study was 
conducted mainly among physicians working in tertiary healthcare facilities in Nigeria and its findings 
may not be completely generalized to physicians in other care settings. However we believe our 
findings may partly reflect the prescribing behaviour and understanding of generic medicines among 
doctors in other settings as more than 10% of the participating physician worked in general 
medical/family medicine specialty. We are also aware there was a greater proportion of male 
physicians taking part in our study at 86% of respondents compared with the normal situation of 75% 
in hospitals. We also accept that using the default option in allocating equal weights to the questions 
LQWKH³NQRZOHGJH´GRPDLQPLJKWEHDVVRFLDWHGZLWKVRPHSUREOHPVFinally, whilst there are 
difficulties in estimating the actual number of medical doctors working in different geo-political regions 
of Nigeria to add further depth to our analysis, data from the Nigerian Medical Association revealed 
that approximately 70% of medical doctors practice in urban areas where most tertiary healthcare 
institutions (including those where some of the study participants practice) are located (100). 
 
However, the sample size, multi-centered nature of the study and the use of previously validated 
instrument in previous studies with good internal constituency are strengths that add robustness to 
the study results and the implications. In addition, the ability to compare findings across countries. 
Consequently, we are confident in the findings and their implications. 
 
We are also aware that cost differences between generics and brand named (originator medicines) 
was not addressed in this study with previous published studies in Nigeria showing the importance of 
the cost of medicines on prescribing choices (65). There is however ample evidence of significant 
cost differences between these two groups of medicines.  In the study conducted by Cameron et al in 
Nigeria and 35 other developing and middle income countries (101), the ratio of the cost of originator 
(branded) to generic medicines for amoxicillin, ciprofloxacin and glibenclamide  was 10, 14 and 9 
respectively (101).In addition, this will be the subject of future papers with recent findings showing 
prices of originator atorvastatin were four times higher in Nigeria than the generic (Onyinye Akunne 
personal communication). Prices of generic simvastatin in Nigeria were also considerably higher than 
those seen in the Netherlands, Sweden or the UK where multiple measures have resulted in generic 
simvastatin (20 and 40mg) costing only US$2 to US$5 per month (25, 102, 103). 
 
Key points 
 
x The prescribing of good quality generics saves considerable resources for patients and health 
care systems without compromising care. This is especially important in Nigeria where the 
healthcare sector is underfunded and there are considerable out-of-pocket payments 
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x However, there have been low rates of generic prescribing in Nigeria contradicting the National 
Standard Treatment Guidelines 
x A cross-sectional questionnaire among physicians in Nigeria ascertained that only 27% had good 
knowledge concerning generics versus 36% with average knowledge and 37% with poor 
knowledge. There was though statistical significance with the duration of medical practice but not 
ZLWKSK\VLFLDQV¶SRVLWLRQVXEVSHFLDOW\RUVH[ 
x The majority of physicians (72% and 69% respectively) did not agree that generic medicines were 
of lower quality than branded (originator) medicines and are associated with greater side-effects. 
In addition, only 15.2% believed generic medicines are less safe than brand (originator) 
medicines 
x An appreciable proportion of physicians believed (44.5%) pharmaceutical companies were a good 
source of information regarding medicines although only 12% admitted being influenced by gifts 
from pharmaceutical companies 
x There is an urgent need to address physician trust in the generics from local manufacturers as 
well as enhance INN prescribing generally. This will benefit local manufacturers as well as 
patients and the healthcare system  
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